

Rec'd PCT/PTO 17 JUN 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number  
WO 2004/056874 A3

(51) International Patent Classification<sup>7</sup>: C07K 16/30,  
16/28, A61K 39/395, A61P 35/00

Kristian, Hobold [DK/DE]; Daiserstrasse 50, 81371  
München (DE).

(21) International Application Number:  
PCT/EP2003/014756

(74) Agents: FLEUCHAUS, Andrea et al.; Melchiorstr.42,  
81479 München (DE).

(22) International Filing Date:  
22 December 2003 (22.12.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/435,893 20 December 2002 (20.12.2002) US  
03000615.9 15 January 2003 (15.01.2003) EP

(71) Applicant (*for all designated States except US*): XERION  
PHARMACEUTICALS AG [DE/DE]; Sauerbruchstr.  
50, 81377 München (DE).

(84) Designated States (*regional*): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for US only*): TUFTS UNIVERSITY  
[US/US]; 136 Harrison Avenue, Boston, MA 02111 (US).

#### Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

(72) Inventors; and

#### Published:

— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(75) Inventors/Applicants (*for US only*): UNGER, Christine,  
Margarete [DE/DE]; Arndt Strasse 11, 80469 München  
(DE). BESTE, Gerald [DE/DE]; Helmpertstr. 2, 80687  
München (DE). ZEHETMEIER, Carolin [DE/DE]; St.  
Martin Strasse 3, 81541 München (DE). LAIN, Blanca  
[ES/US]; 100 Washington St. Apt. 7, Brighton, MA  
02135 (US). TORELLA, Claudia [IT/DE]; Brodstr. 6A,  
81829 München (DE). NIEWÖHNER, Jens [DE/DE];  
Wengleinstrasse 3, 81477 München (DE). JAY, Daniel, G.  
[US/US]; 45 Bigelow Street, Brighton, MA 02135 (US).  
EUSTACE, Brenda, K. [US/US]; 95 Coolidge Street #2,  
Brookline, MA 02446 (US). KNAUER, Roland [DE/DE];  
Gabelsberger Strasse 63, 80333 München (DE). JENSEN,

(88) Date of publication of the international search report:  
9 December 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NEUROPILIN-1 INHIBITORS

(57) Abstract: The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or the metastatic potential of specific tumor cells. Additionally, a method is provided that allows identifying molecules, which interfere with the functionality of neuropilin-1. Furthermore, a method is provided that allows determining whether a naturally occurring tumor cell depends on functional neuropilin-1 for its invasiveness and/or metastatic potential.

WO 2004/056874 A3